Research programme: anti-PD-L1 monoclonal antibody - Development Center for Biotechnology/Unknown
Latest Information Update: 07 Jun 2022
At a glance
- Originator Development Center for Biotechnology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 19 Apr 2022 Early research in Solid tumours in Taiwan (Parenteral) (Development Center for Biotechnology pipeline, April 2022)